drugset / Trial / NCT02759250
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).
Timeline
- Start
- 2015-02
- Primary completion
- 2018-04-25
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cusatuzumab | Monoclonal antibody | 5 mg/kg | — |